Xcout Intel
Biohaven competitors & alternatives
The 12 closest competitors and alternatives to Biohaven among biopharmaceuticals companies — ranked by similarity to what Biohaven actually does, not by market-cap band.
Subscribe to see Biohaven’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Biohaven
Biohaven is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments across key therapeutic areas. Headquartered with operations in New Haven, Connecticut, the company advances innovative neuroscience and specialty therapeutics.
Biohaven at a glance
Biohaven is a biopharmaceuticals company headquartered in United States. Its most recent funding round, Series A, raised $60M in September 2020. Xcout tracks 8 named people at Biohaven, including Vlad Coric, M.D. (Chairman & Chief Executive Officer).
Biohaven leadership
- Vlad Coric, M.D.Chairman & Chief Executive Officer
- Douglas Gray Esq.Corporate Secretary
- Gregory H. Bailey, M.D.Director
- Irina A. Antonijevic, M.D., Ph.D.Director
- John W ChildsDirector
- Julia P GregoryDirector
2 more named people on record for Biohaven, with roles, board committees and tenure — see the full roster →
Biohaven funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $60M | 12 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Biohaven competitors
Ranked by semantic similarity — how close each company is to Biohaven by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biopharmaceuticals company
BioXcel Therapeutics, Inc. is a biopharmaceutical firm that has reached the commercial phase, distinguishing itself by leveraging artificial intelligence to advance the creation of transformative therapies in the fields of neuroscience and immuno-oncology. Their distinctive methodology, termed 'drug re-innovation,' involves harnessing the power of big data and proprietary machine learning algorithms to uncover novel therapeutic applications for existing approved medications or drug candidates with established clinical validation. The company's flagship commercial offering, IGALMI (known during development as BXCL501), is a unique sublingual film delivering dexmedetomidine, designed for the rapid management of agitation experienced by adults with schizophrenia or bipolar I or II disorder. Beyond its current commercial use, BXCL501 is also undergoing further clinical investigation. Studies are underway to assess its efficacy for agitation in individuals with Alzheimer's disease, as an add-on therapy for major depressive disorder, and for use in community settings to address agitation linked to bipolar disorders and schizophrenia. Furthermore, BioXcel is advancing BXCL502, a candidate therapy targeting chronic agitation prevalent in dementia patients. Another key pipeline asset is BXCL701, an orally administered systemic innate immunity activator currently under investigation. This compound shows promise for treating aggressive prostate cancer and advanced solid tumors that have either become resistant to checkpoint inhibitors or have not yet received such treatment. Established in 2017, the company maintains its headquarters in New Haven, Connecticut.
Similar biopharmaceuticals company
AgeneBio, Inc. is a development-stage CNS biopharmaceutical company located in Baltimore, Maryland, focused on discovering and developing innovative therapeutics to preserve and restore brain function.
Drug Discovery
Cognito Therapeutics Ltd. is a clinical-stage company headquartered in Cambridge, Massachusetts, that has conducted multiple clinical studies for its therapeutic products.
Similar biopharmaceuticals company
Axsome Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and developing innovative treatments for central nervous system (CNS) disorders, primarily focusing on the United States market. Its pipeline includes AXS-05, a therapeutic candidate for major depressive disorder and treatment-resistant depression, which is also currently in Phase III clinical trials for Alzheimer's disease agitation and has completed Phase II studies for smoking cessation. The company is also advancing AXS-07, an experimental, rapidly absorbed, oral medication with a multi-mechanistic profile, which has successfully concluded two Phase III trials for the acute treatment of migraine. Another key asset is AXS-12, a selective and potent norepinephrine reuptake inhibitor, presently in Phase III development for narcolepsy. Furthermore, AXS-14, an investigational oral medicine, is undergoing Phase III trials for fibromyalgia. Axsome Therapeutics maintains a research collaboration with Duke University to further evaluate AXS-05 for smoking cessation. The company was founded in 2012 and is headquartered in New York, New York.
Similar biopharmaceuticals company
BrainEver is a privately held biopharmaceutical company headquartered in Paris, France, focused on developing a pipeline of novel therapies.
Drug Discovery
Nura Bio Inc. is a privately held biopharmaceutical company headquartered in South San Francisco, California, founded in 2018 to develop novel treatments for neurological diseases.
Drug Discovery
Object Pharma is a privately held biopharmaceutical company headquartered in Aliso Viejo, California, founded in 2018. The company is dedicated to developing novel treatments for mental health disorders and manufactures botulinum toxin products for accredited research use.
Drug Discovery
Tortugas Neuroscience is a drug discovery and biopharmaceutical company headquartered in Framingham, Massachusetts. The company focuses on advancing innovative neuroscience therapeutics.
Similar biopharmaceuticals company
Cerevel Therapeutics was a U.S. biopharmaceutical company focused on developing medicines for neurological and psychiatric disorders, including schizophrenia, Parkinson’s disease, and Alzheimer’s disease. Its therapies were intended to serve patients with serious central nervous system conditions and the healthcare providers treating them.
Drug Discovery
Stellate Therapeutics is a pre-clinical stage biotechnology company that develops small molecules produced by human gut bacteria into therapies for neurodegenerative and age-related neurological diseases.
Drug Discovery
Courage Therapeutics, Inc. is a for-profit biotechnology company founded in 2019 and headquartered in Newton, Massachusetts. The company operates in the biotech sector with a focus on developing therapeutic solutions.
Similar biopharmaceuticals company
1ST Biotherapeutics is a South Korean biopharmaceutical company focused on discovering and developing treatments for neurodegenerative and other central nervous system diseases. Its work is aimed at patients with disorders such as Alzheimer’s disease and related conditions.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Biohaven and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Biohavenand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →